Results 221 to 230 of about 19,887 (300)

Post-treatment life-trajectories among people who inject drugs who completed hepatitis C treatment with direct acting antivirals: A thematic analysis. [PDF]

Br J Health Psychol
Vojt G, Elliott L, Family H, Sharkey C, Stephens B, Hutchinson S, Hickman M, Dillon JF, Harris M, Flowers P.   +9 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Synthesis and Functional Properties of Fluorinated Phosphonate‐Substituted Porphyrins: Excellent Photosensitizers and Robust Precursors for Photoactive Langmuir–Schaefer Films

Chemistry – A European Journal, EarlyView.
This is a comprehensive study of new family of high functionalized meso‐tetraarylporphyrins. A synthetic approach to phosphonate‐substituted fluorinated porphyrins was developed. These compounds were investigated with respect to singlet oxygen generation and photostability.
Azhar Kechiche, Cyrille Monnereau, Chantal Andraud, Alla Bessmertnykh‐Lemeune, Yoann Rousselin, Andrey V. Cheprakov, Elizaveta V. Ermakova, Alexandra I. Zvyagina, Habib Nasri   +8 more
wiley   +1 more source

Retraction: Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection. [PDF]

Cureus
Chowdhury R, Rashid W, Singh T, Rehman A, Daterdiwala NF, Mkosi V, Limbu B, Bukhari SA, Ramadhan A, Dabas MM, Shehryar A, Khan R.   +11 more
europepmc   +1 more source

Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnant individuals take drugs throughout pregnancy and many of these drugs (e.g., antivirals, antibiotics) are eliminated by renal organic anion transporters (OAT) 1 and OAT3. In vivo studies with OAT1/3 substrate drugs suggest that pregnancy increases renal OAT1/3 activities by 1.5‐ to 1.8‐fold.
Aarzoo Thakur, Jashvant D. Unadkat, Emily E. Fay, Nina Isoherranen, Mary F. Hebert   +4 more
wiley   +1 more source

Modulation of glucose metabolism and insulin resistance following hepatitis C virus clearance via direct-acting antivirals. [PDF]

Sci Rep
Jabeen S, Khan R, Alrashed MM, Ullah S, Nabi G, Ullah MI, Waqar AB, Attia KA, Kimiko I.   +8 more
europepmc   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

The Role of Direct-Acting Antivirals in Enhancing Quality of Life Among Individuals with Chronic Hepatitis C. [PDF]

Healthcare (Basel)
Pirlog MC, Danilescu CM, Alexandru DO, Streba CT, Rogoveanu I.   +4 more
europepmc   +1 more source

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) is a potent, pan‐genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log10 ...
Carolin Zitzmann, Ruy M. Ribeiro, Aurélien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source